Trials / Terminated
TerminatedNCT04383210
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Elevation Oncology · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
Conditions
- Locally Advanced Solid Tumor
- Metastatic Solid Tumor
- Pancreatic Cancer
- Lung Cancer
- Head and Neck Cancer
- Breast Cancer
- Kidney Cancer
- Colorectal Cancer
- Bladder Cancer
- Ovarian Cancer
- Sarcoma
- Gallbladder Cancer
- Bile Duct Cancer
- Esophageal Cancer
- Uterine Cancer
- Cholangiocarcinoma
- Prostate Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Seribantumab | Anti-HER3 monoclonal antibody |
Timeline
- Start date
- 2020-09-29
- Primary completion
- 2024-02-28
- Completion
- 2024-02-28
- First posted
- 2020-05-12
- Last updated
- 2025-04-03
- Results posted
- 2025-04-03
Locations
42 sites across 4 countries: United States, Australia, Canada, South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04383210. Inclusion in this directory is not an endorsement.